Significance of neurodegeneration and neuroplasticity serum biomarkers in Parkinson’s disease patients treated with subthalamic stimulation

The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson’s disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	NPJ Parkinson's Disease 2024-10, Vol.10 (1), p.197-6, Article 197
Hauptverfasser:	Sanmartino, Florencia, Cano-Cano, Fátima, Rashid-López, Raúl, Cruz-Gómez, Álvaro Javier, Lozano-Soto, Elena, Macías-García, Paloma, Sánchez-Fernández, Francisco L., López-Sosa, Fernando, Gómez-Jaramillo, Laura, Riqué-Dormido, Jesús, Escamilla-Sevilla, Francisco, Espinosa-Rosso, Raúl, González-Rosa, Javier J.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/53/2422 692/617/375/346/1718 Biomarkers Biomedical and Life Sciences Biomedicine Brain research Brain-derived neurotrophic factor Brief Communication Electrodes Hospitals Medical prognosis Neurodegeneration Neurology Neuroplasticity Neurosciences Patients Postoperative period Proteins Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson’s disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transiently after DBS surgery. Therefore, subthalamic stimulation does not promote neurodegeneration, and these biomarkers do not serve as clinical improvement endpoints in PD DBS patients.
ISSN:	2373-8057 2373-8057
DOI:	10.1038/s41531-024-00808-w